Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antuss Plus is an oral combination medication developed by Gaco Pharmaceuticals, designed for the symptomatic relief of coughs and congestion associated with the common cold and respiratory infections. The formulation contains three active ingredients: diphenhydramine hydrochloride, guaifenesin, and levomenthol. Diphenhydramine is a first-generation antihistamine that acts as an H1-receptor antagonist, providing antitussive effects by reducing the cough reflex and alleviating allergic symptoms. Guaifenesin is an expectorant that works by increasing the volume and reducing the viscosity of respiratory tract secretions, thereby facilitating the clearance of mucus from the airways. Levomenthol provides a cooling sensation and mild local anesthetic effect on the throat and nasal passages by acting as a TRPM8 agonist. Together, these components address both productive and non-productive coughs while soothing irritated respiratory tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diphenhydramine + guaifenesin + levomenthol.